Vaniprevir (MK-7009) is a macrocyclic hepatitis C virus (HCV) NS3/4A protease inhibitor, developed by Merck & Co., which is currently in clinical testing.

[1] In Japan, it was approved for treating hepatitis C in 2014 under the brand name Vanihep.

[2][3] This antiinfective drug article is a stub.

You can help Wikipedia by expanding it.